Citations

Showing 10 of 108104 citations.

Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast Cancer
Sparano, Joseph A. , O’Neill, Anne, Alpaugh, Katherine, Northfelt, Donald W. , Dang, Chau T. , Sparano, Joseph A , Wolff, Antonio C. , Sledge, George W. , Miller, Kathy D.

Mayo Clinic

JAMA Oncology | July 26, 2018 | Volume: 4 | Issue: 12 | Pages: 1700

10.1001/jamaoncol.2018.2574 | PMID 30054636 Get It

The 2018 Revision to the Process of Care Model for Evaluation of Erectile Dysfunction
Mulhall, John P. , Giraldi, Annamaria , Hackett, Geoff , Hellstrom, Wayne J.G. , Rubio‐Aurioles, Eusebio , Trost, Landon , Hassan, Tarek A. , Hackett, Geoffrey , Jannini, Emmanuele A. , Hassan, Tarek A.

Mayo Clinic

The Journal of Sexual Medicine | July 26, 2018 | Volume: 15 | Issue: 9 | Pages: 1280-1292

10.1016/j.jsxm.2018.06.005 | PMID 30057280 Get It

Abstract Background Erectile dysfunction (ED) is a common condition that may affect men of all ages; in 1999, a Process of Care Model was developed to provide clinicians with recommendations regarding the evaluation and management of ED. Aim To reflect the evolution of the study of ED since 1999, this update to the process of care model presents health care providers with a tool kit to facilitate patient interactions, comprehensive evaluation, and counseling for ED. Methods A cross-disciplinary panel of international experts met to propose updates to the 1999 process of care model from a global perspective. The updated model was designed to be evidence-based, data-driven, and accessible to a wide range of health care providers. Outcomes This article summarizes the resulting discussion of the expert meeting and focuses on ED evaluation. The management of ED is discussed in an article by Muhall et al (J Sex Med 2018;15:1280-1292). Results A comprehensive approach to the evaluation of ED is warranted because ED may involve both psychological and organic components. The updated process of care model for evaluation was divided into core and optional components and now focuses on the combination of first-line pharmacotherapy and counseling in consideration of patient sexual dynamics. Clinical Implications Patient evaluation for ED should encompass a variety of aspects, including medical history, sexual history, physical examination, psychological evaluation, laboratory testing, and possibly adjunctive testing. Strengths & Limitations This update draws on author expertise and experience to provide multi-faceted guidance for the evaluation of ED in a modern context. Although a limited number of contributors provided input on the update, these experts represent diverse fields that encounter patients with ED. Additionally, no meta-analyses were performed to further support the ED evaluation guidelines presented. Conclusion Comprehensive evaluation of ED affords health care providers an opportunity to address medical, psychological/psycho-social, and sexual issues associated with ED, with the ultimate goal being effective management and possibly resolution of ED. While some or all techniques described in the updated model may be needed for each patient, evaluation should in all cases be thorough.
The 2018 Revision to the Process of Care Model for Management of Erectile Dysfunction
Mulhall, John P. , Giraldi, Annamaria , Hackett, Geoff , Hellstrom, Wayne J.G. , Rubio‐Aurioles, Eusebio , Trost, Landon , Hassan, Tarek A. , Hackett, Geoffrey , Jannini, Emmanuele A. , Hassan, Tarek A.

Mayo Clinic

The Journal of Sexual Medicine | July 26, 2018 | Volume: 15 | Issue: 10 | Pages: 1434-1445

10.1016/j.jsxm.2018.05.021 | PMID 30057278 Get It

Abstract Introduction Erectile dysfunction (ED) is a common condition the treatment of which over the years has expanded from specialty care settings to various other clinical settings. A Process of Care Model was developed in 1999 to provide primary care physicians with guidance in the diagnosis and management of ED. Aim This update to the Process of Care Model aims to reflect current ED management practices, because the study of ED has changed since 1999. Methods Updates to the Process of Care Model were developed during a meeting of international experts from diverse disciplines. The updated model is data-driven, evidence-based, and relevant to a wide range of healthcare providers. Main Outcome Measures This article summarizes the results of the expert meeting and focuses on ED management. The evaluation of ED is discussed in a separate article. Results The updated model presents modification of risk factors and correction of comorbidities frequently associated with ED as critical parts of patient management. Patients should be encouraged to make positive lifestyle changes such as improving diet and increasing physical exercise. Lifestyle changes may be accompanied by the first-line medical therapies of sexual counseling and therapy, which takes into consideration patient sexual dynamics and pharmacotherapy with phosphodiesterase 5 inhibitors (PDE5Is). Clinical Implications The updated model provides guidance regarding risk factors associated with ED, their modification, sexual counseling, and PDE5I selection, dosing, and patient education. Strengths and Limitations This update leverages the extensive clinical expertise and experience of the authors to provide updated, comprehensive guidance for ED management. The model reflects the views and experiences of a limited number of contributors; however, these authors draw upon a diverse array of clinical specialties and are regarded as experts in their fields. Additionally, no meta-analyses were performed to further support the ED evaluation guidelines presented. Conclusion Effective management of ED may be achieved through a combination of patient risk factor modification and first-line therapy, taking into consideration any patient comorbidities known to be associated with ED. Treatment goals should be individualized to restore sexual satisfaction to the patient and/or couple and improve quality of life based on the patient’s expressed needs and desires.
Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease
Weinshenker, Brian G. , Kantarci, Orhun H. , Schmalstieg, William F., Soldán, M. Mateo Paz , Weinshenker, Brian G , Keegan, B. Mark , Kaufmann, Timothy J. , Flanagan, Eoin P. , Paz Soldán, M Mateo

Mayo Clinic

Multiple Sclerosis Journal | July 26, 2018 | Volume: 24 | Issue: 11 | Pages: 1445-1452

10.1177/1352458518781979 | PMID 30047830 Get It

Objective: To report progressive motor impairment from a critically located central nervous system (CNS) demyelinating lesion in patients with restricted magnetic resonance imaging (MRI)-lesion burden. Methods: We identified 38 patients with progressive upper motor-neuron impairment for >1 year, 2–5 MRI CNS-demyelinating lesions, with one seemingly anatomically responsible for progressive motor impairment. Patients with any alternative etiology for progressive motor impairment were excluded. A neuroradiologist blinded to clinical evaluation reviewed multiple brain and spinal-cord MRI, selecting a candidate critically located demyelinating lesion. Lesion characteristics were determined and subsequently compared with clinical course. Results: Median onset age was 47.5 years (24–64); 23 (61%) women. Median follow-up was 94 months (18–442); median Expanded Disability Status Scale Score (EDSS) at last follow-up was 4.5 (2–10). Clinical presentations were progressive: hemiparesis/monoparesis 31; quadriparesis 5; and paraparesis 2; 27 patients had progression from onset; 11 progression post-relapse. Total MRI lesions were 2 ( n = 8), 3 ( n = 12), 4 ( n = 12), and 5 ( n = 6). Critical lesions were located on corticospinal tracts, chronically atrophic in 26/38 (68%) and involved cervical spinal cord in 27, cervicomedullary/brainstem region in 6, thoracic spinal cord in 4, and subcortical white matter in 1. Conclusion: Progressive motor impairment may ascribe to a critically located CNS-demyelinating lesion in patients with highly restricted MRI burden. Motor progression from a specific demyelinating lesion has implications for understanding multiple sclerosis (MS) progression.
Faculty Opinions recommendation of Prevalence of irritable bowel syndrome and chronic fatigue 10 years after giardia infection.
Grover, Madhusudan

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 26, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732579579.793548496 Get It

Feasibility trial of an unsupervised, facility-based exercise programme for depressed outpatients
Patten, Christi A. , Vickers, Kristin S. , Lewis, Beth A. , Finnie, Steven B., Wheeldon, Theresa J., Decker, Paul A. , Stevens, S. Elizabeth, Hathaway, Julie, Reese, Michael, Seime, Richard J., Hathaway, Julie C, Reese, Michael M, Patten, Christi , Decker, Paul A.

Mayo Clinic

Psychology, Health & Medicine | July 26, 2018 | Volume: 24 | Issue: 3 | Pages: 320-332

10.1080/13548506.2018.1499944 | PMID 30047802 Get It

M 3 RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction
Singh, Raman Deep , Hillestad, Matthew L. , Livia, Christopher , Alekseev, Alexey E., Witt, Tyra A. , Stalboerger, Paul G., Behfar, Atta , Yamada, Satsuki , Behfar, Atta , Livia, Christopher , Li, Mark, Terzic, André

Mayo Clinic

Tissue Engineering Part A | July 26, 2018 | Volume: 25 | Issue: 1-2 | Pages: 145-158

10.1089/ten.tea.2017.0445 | PMID 30047313 Get It

A droplet microfluidic platform for efficient enzymatic chromatin digestion enables robust determination of nucleosome positioning
Xu, Yi , Lee, Jeong‐Heon , Li, Zhaoyu , Wang, Liguo , Ördög, Tamás , Li, Zhaoyu , Lee, Jeong-Heon , Wang, Liguo , Bailey, Ryan C

Mayo Clinic

Lab on a Chip | July 26, 2018 | Volume: 18 | Issue: 17 | Pages: 2583-2592

10.1039/c8lc00599k | PMID 30046796 Get It

A microfluidic device was designed to efficiently fragment chromatin for downstream epigenetic assays.
The cortisol stress response induced by surgery: A systematic review and meta‐analysis
Prete, Alessandro , Yan, Qi , Al‐Tarrah, Khaled , Aktürk, Halis Kaan , Alahdab, Fares , Foster, Mark , Lord, Janet M. , Karavitaki, Niki , Wass, John , Murad, M. Hassan , Arlt, Wiebke , Akturk, Halis K , Karavitaki, Niki , Murad, Mohammad H, Bancos, Irina , Murad, M Hassan , Arlt, Wiebke , Prete, Alessandro , Yan, Qi , Prokop, Larry J. , Bancos, Irina , Alahdab, Fares

Mayo Clinic

Clinical Endocrinology | July 26, 2018 | Volume: 89 | Issue: 5 | Pages: 554-567

10.1111/cen.13820 | PMID 30047158 Get It

Summary Objective Surgery is a stressor that can be categorized by duration and severity and induces a systemic stress response that includes increased adrenal cortisol production. However, the precise impact of surgical stress on the cortisol response remains to be defined. Design We performed a systematic review and meta‐analysis to assess the cortisol stress response induced by surgery and to stratify this response according to different parameters. Methods We conducted a comprehensive search in several databases from 1990 to 2016. Pairs of reviewers independently selected studies, extracted data and evaluated the risk of bias. Cortisol concentrations were standardized, pooled in meta‐analysis and plotted over time. Results We included 71 studies reporting peri‐operative serum cortisol measurements in 2953 patients. The cortisol response differed substantially between moderately/highly invasive and minimally invasive surgical procedures. Minimally invasive procedures did not show a peri‐operative cortisol peak, whereas more invasive surgeries caused a cortisol surge that was more pronounced in older subjects, women and patients undergoing open surgery and general anaesthesia. The duration of the procedure and the use of etomidate for induction of anaesthesia did not affect the cortisol response. Conclusions The peri‐operative cortisol stress response is dynamic and influenced by patient‐specific, surgical and anaesthetic features. However, the available evidence is derived from highly heterogeneous studies, with only two of 71 studies measuring cortisol by mass spectrometry, which currently prevents a precise and reproducible definition of this response.
‘Watch and wait’ after chemoradiotherapy for rectal cancer
Mullaney, T G, Johnston, Michael , Keck, James, Wattchow, David A. , Mullaney, Tamara G , Lightner, Amy L.

Mayo Clinic

ANZ Journal of Surgery | July 26, 2018 | Volume: 88 | Issue: 9 | Pages: 836-841

10.1111/ans.14352 | PMID 30047201 Get It

Surgery remains the cornerstone of rectal cancer treatment. However, there is significant morbidity and mortality associated with pelvic surgery, and the past decade has illustrated that a cohort of rectal cancer patients sustain a remission of local disease with chemoradiation alone. Thus, questions remain regarding the optimal management for rectal cancer; namely, accurately identifying patients who have a complete pathologic response and determining the oncologic safety of the observational approach for this patient group. This review aims to summarize the current evidence to provide an overview to the ‘watch and wait’ approach in rectal cancer patients with a complete response to neoadjuvant chemoradiation therapy.